Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1950 1
1952 1
1961 1
1970 1
1994 1
1996 2
1998 3
2002 1
2003 2
2004 3
2005 5
2006 5
2007 4
2008 7
2009 8
2010 8
2011 9
2012 12
2013 7
2014 15
2015 15
2016 19
2017 21
2018 25
2019 18
2020 31
2021 26
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

217 results
Results by year
Filters applied: . Clear all
Page 1
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A'Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, de Bono JS. Mateo J, et al. Among authors: figueiredo i. N Engl J Med. 2015 Oct 29;373(18):1697-708. doi: 10.1056/NEJMoa1506859. N Engl J Med. 2015. PMID: 26510020 Free PMC article. Clinical Trial.
Role of pharmacist during the COVID-19 pandemic: A scoping review.
Visacri MB, Figueiredo IV, Lima TM. Visacri MB, et al. Among authors: figueiredo iv. Res Social Adm Pharm. 2021 Jan;17(1):1799-1806. doi: 10.1016/j.sapharm.2020.07.003. Epub 2020 Jul 4. Res Social Adm Pharm. 2021. PMID: 33317760 Free PMC article. Review.
Genomics of lethal prostate cancer at diagnosis and castration resistance.
Mateo J, Seed G, Bertan C, Rescigno P, Dolling D, Figueiredo I, Miranda S, Nava Rodrigues D, Gurel B, Clarke M, Atkin M, Chandler R, Messina C, Sumanasuriya S, Bianchini D, Barrero M, Petermolo A, Zafeiriou Z, Fontes M, Perez-Lopez R, Tunariu N, Fulton B, Jones R, McGovern U, Ralph C, Varughese M, Parikh O, Jain S, Elliott T, Sandhu S, Porta N, Hall E, Yuan W, Carreira S, de Bono JS. Mateo J, et al. Among authors: figueiredo i. J Clin Invest. 2020 Apr 1;130(4):1743-1751. doi: 10.1172/JCI132031. J Clin Invest. 2020. PMID: 31874108 Free PMC article. Clinical Trial.
Targeting the p300/CBP Axis in Lethal Prostate Cancer.
Welti J, Sharp A, Brooks N, Yuan W, McNair C, Chand SN, Pal A, Figueiredo I, Riisnaes R, Gurel B, Rekowski J, Bogdan D, West W, Young B, Raja M, Prosser A, Lane J, Thomson S, Worthington J, Onions S, Shannon J, Paoletta S, Brown R, Smyth D, Harbottle GW, Gil VS, Miranda S, Crespo M, Ferreira A, Pereira R, Tunariu N, Carreira S, Neeb AJ, Ning J, Swain A, Taddei D; SU2C/PCF International Prostate Cancer Dream Team, Schiewer MJ, Knudsen KE, Pegg N, de Bono JS. Welti J, et al. Among authors: figueiredo i. Cancer Discov. 2021 May;11(5):1118-1137. doi: 10.1158/2159-8290.CD-20-0751. Epub 2021 Jan 11. Cancer Discov. 2021. PMID: 33431496 Free PMC article.
Characterizing CDK12-Mutated Prostate Cancers.
Rescigno P, Gurel B, Pereira R, Crespo M, Rekowski J, Rediti M, Barrero M, Mateo J, Bianchini D, Messina C, Fenor de la Maza MD, Chandran K, Carmichael J, Guo C, Paschalis A, Sharp A, Seed G, Figueiredo I, Lambros M, Miranda S, Ferreira A, Bertan C, Riisnaes R, Porta N, Yuan W, Carreira S, de Bono JS. Rescigno P, et al. Among authors: figueiredo i. Clin Cancer Res. 2021 Jan 15;27(2):566-574. doi: 10.1158/1078-0432.CCR-20-2371. Epub 2020 Sep 28. Clin Cancer Res. 2021. PMID: 32988971 Free PMC article.
CD38 in Advanced Prostate Cancers.
Guo C, Crespo M, Gurel B, Dolling D, Rekowski J, Sharp A, Petremolo A, Sumanasuriya S, Rodrigues DN, Ferreira A, Pereira R, Figueiredo I, Mehra N, Lambros MBK, Neeb A, Gil V, Seed G, Terstappen L, Alimonti A, Drake CG, Yuan W, de Bono JS; International SU2C PCF Prostate Cancer Dream Team. Guo C, et al. Among authors: figueiredo i. Eur Urol. 2021 Jun;79(6):736-746. doi: 10.1016/j.eururo.2021.01.017. Epub 2021 Mar 5. Eur Urol. 2021. PMID: 33678520 Free PMC article.
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.
Neeb A, Herranz N, Arce-Gallego S, Miranda S, Buroni L, Yuan W, Athie A, Casals T, Carmichael J, Rodrigues DN, Gurel B, Rescigno P, Rekowski J, Welti J, Riisnaes R, Gil V, Ning J, Wagner V, Casanova-Salas I, Cordoba S, Castro N, Fenor de la Maza MD, Seed G, Chandran K, Ferreira A, Figueiredo I, Bertan C, Bianchini D, Aversa C, Paschalis A, Gonzalez M, Morales-Barrera R, Suarez C, Carles J, Swain A, Sharp A, Gil J, Serra V, Lord C, Carreira S, Mateo J, de Bono JS. Neeb A, et al. Among authors: figueiredo i. Eur Urol. 2021 Feb;79(2):200-211. doi: 10.1016/j.eururo.2020.10.029. Epub 2020 Nov 8. Eur Urol. 2021. PMID: 33176972 Free article.
CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo.
Alajati A, D'Ambrosio M, Troiani M, Mosole S, Pellegrini L, Chen J, Revandkar A, Bolis M, Theurillat JP, Guccini I, Losa M, Calcinotto A, De Bernardis G, Pasquini E, D'Antuono R, Sharp A, Figueiredo I, Nava Rodrigues D, Welti J, Gil V, Yuan W, Vlajnic T, Bubendorf L, Chiorino G, Gnetti L, Torrano V, Carracedo A, Camplese L, Hirabayashi S, Canato E, Pasut G, Montopoli M, Rüschoff JH, Wild P, Moch H, De Bono J, Alimonti A. Alajati A, et al. Among authors: figueiredo i. J Clin Invest. 2020 May 1;130(5):2435-2450. doi: 10.1172/JCI131133. J Clin Invest. 2020. PMID: 32250342 Free PMC article.
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.
Carreira S, Porta N, Arce-Gallego S, Seed G, Llop-Guevara A, Bianchini D, Rescigno P, Paschalis A, Bertan C, Baker C, Goodall J, Miranda S, Riisnaes R, Figueiredo I, Ferreira A, Pereira R, Crespo M, Gurel B, Nava Rodrigues D, Pettitt SJ, Yuan W, Serra V, Rekowski J, Lord CJ, Hall E, Mateo J, de Bono JS. Carreira S, et al. Among authors: figueiredo i. Cancer Discov. 2021 Nov;11(11):2812-2827. doi: 10.1158/2159-8290.CD-21-0007. Epub 2021 May 27. Cancer Discov. 2021. PMID: 34045297 Free article.
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R, Syndikus I, Ralph C, Jain S, Varughese M, Parikh O, Crabb S, Robinson A, McLaren D, Birtle A, Tanguay J, Miranda S, Figueiredo I, Seed G, Bertan C, Flohr P, Ebbs B, Rescigno P, Fowler G, Ferreira A, Riisnaes R, Pereira R, Curcean A, Chandler R, Clarke M, Gurel B, Crespo M, Nava Rodrigues D, Sandhu S, Espinasse A, Chatfield P, Tunariu N, Yuan W, Hall E, Carreira S, de Bono JS. Mateo J, et al. Among authors: figueiredo i. Lancet Oncol. 2020 Jan;21(1):162-174. doi: 10.1016/S1470-2045(19)30684-9. Epub 2019 Dec 2. Lancet Oncol. 2020. PMID: 31806540 Free PMC article. Clinical Trial.
217 results